Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy

David M Fleischer, MD

Professor of Pediatrics and Section Head
Children's Hospital Colorado
University of Colorado School of Medicine, Aurora, CO, USA

On behalf of: Dianne E Campbell, Paul Kearney, Bob Getts, Todd D Green, Hugh A Sampson

ACAAI 2020 Annual Scientific Meeting

Background

- Epicutaneous immunotherapy (EPIT) is currently under investigation for the treatment of peanut allergy
  - **DBV712 250 µg** is a single, daily-dose patch applied to the back and is dosed at 250 µg (**~1/1000 of a peanut**)[1-3]
- Existing biomarkers such as total peanut-IgE and SPT used in the diagnosis of peanut allergy are not adequate for quantifying desensitization during immunotherapy
- Total peanut-IgG4 during EPIT is not highly correlated with treatment response during immunotherapy
- Measuring IgE and IgG4 reactivity to **epitopes** (smaller fragments of allergen to which an allergic individual can produce an antibody) from peanut protein allergens may help to quantify desensitization during EPIT

SPT=skin prick test.

1. Sampson HA, et al. *JAMA*. 2017;318:1798-1809. **2.** Tilles SA, et al. *Ann Allergy Asthma Immunol*. 2018;121:145-149. **3.** Parrish CP. *Am J Manag Care*. 2018;24:S419-S427.

Aims and Objectives

- Assess performance of the **Bead-Based Epitope Assay** (BBEA), which enables simultaneous quantification of antibodies recognizing sequential linear protein epitopes, in predicting desensitization during EPIT

- The specific **objectives** of the study were to:
  - Analyze the samples from subjects who participated in PEPITES (Phase 3 DBRCT of DBV712 250 µg in peanut allergic children) for IgE and IgG4 reactivity to Ara h 1, Ara h 2, and Ara h 3 peanut allergen epitopes using the BBEA
  - Derive predictors of desensitization progress over time as well as predictors of desensitization above a peanut protein eliciting dose threshold (>300 mg) following 12 months of treatment with DBV712 250 µg

DBRCT=double-blind randomized controlled trial.

Methods: BBEA Technology[1]

- A **Bead-Based Epitope Assay** (BBEA) platform was used to monitor the reactivity of **IgE and IgG4** in subjects' serum to 64 linear **epitopes** from Ara h 1, Ara h 2, and Ara h 3





- The BBEA methodology enables simultaneous quantification of antibodies binding to sequential epitopes
- Epitopes are covalently coupled to unique fluorescent microspheres (Luminex)
- Epitope-labeled beads are mixed to form a master library
- Patient plasma and a secondary fluorophore-labeled antibody are then incubated with the beads
- The Luminex instrument uses dual-lasers for quantification (red for beads, green for secondary antibodies)
- For each epitope, the signal is quantified as a median fluorescence intensity (MFI)

Figure adapted from Suprun et al.[1] (http://creativecommons.org/licenses/by/4.0/)

1. Suprun M, et al. *Sci Rep.* 2019;9:18425. doi.org/10.1038/s41598-019-54868-7.

Methods: Subjects and Samples

Subjects

- **89 peanut-allergic subjects** who participated in the 12-month, randomized, double-blind, placebo-controlled **PEPITES** study[1]
  - Subjects received active treatment with DBV712 250 µg (n=61) or placebo (n=28)

Samples

- Serum samples were analyzed using the BBEA at 0, 3, 6, and 12 months for IgE and IgG4 reactivity to 64 linear epitopes from Ara h 1, Ara h 2, and Ara h 3 (esIgE and esIgG4)
  - The BBEA method was applied under SOPs to all subjects in triplicate and randomized across plates
  - Raw data was processed: noise removal, log normalized, triplicates merged
  - Analysis was performed using linear regression models
  - Accuracy, sensitivity, specificity, and AUC were generated
- Serum samples were analyzed for total peanut-specific IgE and IgG4

AUC=area under the curve; BBEA=Bead-Based Epitope Assay; esIgE=epitope-specific IgE; esIgG4=epitope-specific IgG4; SOP=standard operating procedure.

1. Fleischer DM, et al. *JAMA*. 2019;321(10):946-955.

Methods: Endpoints

Endpoints

- **Threshold desensitization** was defined as an eliciting dose (ED) >300 mg peanut protein at Month 12 (ie, ≥1000 mg) irrespective of baseline ED (all ≤300 mg)
- **Progressive desensitization** was defined as ED threshold increased by at least 1 dose from baseline to Month 12



Results: Epitope Mapping – Progressive and Threshold Desensitization Predictors

Threshold Desensitization (ED ≥1000 mg)

	12 Months
Best epitopes (IgG4)	*h2.010* *h3.102* *h1.029* *h1.090*
AUC	**0.97**
% accuracy (95% CI)	93% (90, 98)

Progressive Desensitization (Improvement in ED)

	12 Months
Best epitopes (IgE)	h1.041 h1.022 h2.008
AUC	**0.92**
% accuracy (95% CI)	91% (83, 93)

- Addition of baseline subject characteristics or AE rate during treatment did not improve performance in either analysis

AE=adverse event; AUC=area under the curve; CI=confidence interval; ED=eliciting dose.

Results: esIgE and esIgG4 to h2.008 Reactivity for All Subjects





- For epitopes such as h2.008, treatment increased IgG4 reactivity to epitopes over time
- Similar behavior was seen for h1.029

esIgE=epitope-specific IgE; esIgG4=epitope-specific IgG4.

Results: Threshold Desensitization

Threshold Desensitization at Month 12 – 4 Epitope Linear Regression Model (IgG4)

	Coefficient	SE	tStats	*P* value
(Intercept)	-0.535	1.593	-0.336	0.737
h2.010	6.357	3.312	1.919	0.055
h3.102	-5.910	2.970	-2.033	0.042
h1.029	-7.037	2.667	-2.639	0.008
h1.090	6.339	2.579	2.458	0.014
Chi^2-statistic vs constant model: 41.9, *P* value =1.77e-08, **AUC=0.97**				

AUC=area under the curve; SE=standard error.

Results: Progressive Desensitization at Month 12

Progressive Desensitization at Month 12 – 3 Epitope Linear Regression Model (IgE)

	Coefficient	SE	tStats	*P* value
(Intercept)	6.932	2.361	2.936	0.0033
h1.041	-0.634	0.279	-2.271	0.0232
h1.022	0.585	0.237	2.463	0.0138
h2.008	-0.423	0.226	-1.872	0.0612
Chi^2-statistic vs constant model: 23.2, *P*=3.71e-05, **AUC=0.92**				

AUC=area under the curve; SE=standard error.

Results: Progressive Desensitization Over Time

Progressive Desensitization

	3 Months	6 Months	12 Months
Best epitopes (IgE)	h1.041 h1.022 h2.008	h1.041 h1.022 h2.008	h1.041 h1.022 h2.008
AUC	0.90	0.91	0.92
% accuracy	89%	89%	91%



Scores above 1 indicate progressive desensitization over time.

AUC=area under the curve.

Results: Responders vs Non-Responders vs Placebo – Epitopes h1.029 and h2.008









- IgG4 reactivity to each epitope differentiated between placebo, responders, and non-responders with a markedly different trajectory over the 12 months by group
- Faster increases in IgG4 reactivity to h1.029 and h2.008 was associated with treatment response
- IgE reactivity to h1.029 and h2.008 remained stable or slightly declined over 12 months of treatment

Results: Comparison of esIgE/IgG4 to Total Peanut-sIgE/sIgG4

Total peanut-sIgE and sIgG4/sIgE were demonstrated to be poorer predictors of progressive desensitization, with AUCs of 68% and 64%, respectively, at 12 months

sIgE Predictor of Progression Desensitization

	Coefficient	SE	tStats	*P* value
(Intercept)	1.4447	0.45808	3.1538	0.0016113
x1 [h1.041]	-0.0012408	0.0010524	-1.1789	0.23842
Chi^2-statistic vs constant model: 1.36, *P*=0.244, **AUC=0.68382**				

sIgE and sIgG4 Predictor of Progression Desensitization

	Coefficient	SE	tStats	*P* value
(Intercept)	1.2014	0.53651	2.2392	0.025142
x1 [h1.041]	-0.0016422	0.0011868	-1.3837	0.16644
x2 [h1.022]	0.061838	0.076652	0.80674	0.41981
Chi^2-statistic vs constant model: 2.14, *P*=0.344, **AUC=0.64216**				

AUC=area under the curve; esIgE=epitope-specific IgE; esIgG4=epitope-specific IgG4; SE=standard error; sIgE=peanut-specific IgE; sIgG4=peanut-specific IgG4.

Summary and Future Directions

BBEA may be a highly accurate tool for monitoring desensitization during EPIT

- Highly accurate models for predicting both threshold and progressive desensitization were able to be built using 3, 4, and 5 epitope (esIgE and esIgG4) algorithms
- Overall peanut-esIgE reactivity did not change significantly with treatment over time, while peanut-esIgG4 reactivity increased
- Faster increases in esIgG4 reactivity to h1.029 and h2.008 were associated with treatment response
- Lower esIgE reactivity to h1.029 and h2.008 was associated with response to treatment
- Total peanut-sIgE and/or sIgG4 were shown to be relatively poor predictors of progressive desensitization in this population
- Analyses are ongoing to validate these findings in a larger sample and to examine predictors for desensitization beyond 12 months

BBEA=Bead-Based Epitope Assay; EPIT=epicutaneous immunotherapy; esIgE=epitope-specific IgE; esIgG4=epitope-specific IgG4; sIgE=peanut-specific IgE; sIgG4=peanut-specific IgG4.

Acknowledgements

Dianne E Campbell[1,2], Paul Kearney[3], Bob Getts[3], Todd D Green[2,4], David M Fleischer[5], Hugh A Sampson[2,6]

1. Children's Hospital at Westmead, Sydney
2. DBV Technologies SA, Montrouge, France
3. AllerGenis, Hatfield, PA, USA
4. UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
5. Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA
6. Department of Pediatrics, Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA